Uterine papillary serous carcinoma. Evaluation of long-term survival in surgically staged patients

被引:112
作者
Grice, J [1 ]
Ek, M
Greer, B
Koh, WJ
Muntz, HG
Cain, J
Tamimi, H
Stelzer, K
Figge, D
Goff, BA
机构
[1] Dept Gynecol & Obstet, Div Gynecol Oncol, Seattle, WA 98195 USA
[2] Dept Pathol, Seattle, WA 98195 USA
[3] Dept Radiat Oncol, Seattle, WA 98195 USA
[4] Virginia Mason Med Ctr, Seattle, WA 98111 USA
[5] Penn State Univ, Milton S Hershey Med Ctr, Dept Obstet & Gynecol, Hershey, PA 17033 USA
关键词
D O I
10.1006/gyno.1998.4956
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Earlier studies have demonstrated that the uterine papillary serous carcinoma (UPSC) variant of endometrial carcinoma has a high recurrence rate, even when disease is apparently confined to the uterus. The current study evaluated survival in patients with surgically staged UPSC. Methods. Patients with UPSC were identified from surgical pathology files and charts were retrospectively reviewed. Only patients who had undergone a TAH-BSO, lymph node dissection, and peritoneal cytology were included. Results. The FIGO stages of the 36 patients were 12 Stage I (4 IA, 4 IB, 4 IC), 2 Stage IIB, 13 Stage III (5 IIIA, 8 IIIC), and 9 Stage IV. Of the 14 Stage I/II patients, 6 did not receive adjuvant therapy, 5 received whole pelvic radiation (WPXRT), and 3 received whole abdominal radiation therapy (WART); after a median follow-up interval of 50 months only 2 (14%) of these Stage I/II patients have developed a recurrence. Both of the recurrences were in Stage IC patients who received radiation; 1 recurred in the radiation field, Of the 5 Stage IIIA patients, 3 patients declined therapy and 2 were treated with WART; 3 patients, including the 2 who received radiation therapy, are alive without disease. Of the 8 Stage IIIC patients, 2 declined postoperative therapy, 2 received WART, and 3 received WPXRT with an extended held to include paraaortic nodes. Four of the 6 Stage IIIC patients treated with curative intent are without evidence of disease and 1 died of unrelated causes after a median follow-up interval of 48 months. Both of the Stage IIIC patients who declined treatment recurred. Of the 9 patients with Stage IV disease, 8 have died of disease. Conclusion. Women with UPSC have a good prognosis when surgical staging confirms that disease is confined to the uterus (Stage I/II). Surgical findings can also be used to tailor adjuvant radiation treatments. Further study is required to define the optimal treatment for women with metastatic UPSC. (C) 1998 Academic Press.
引用
收藏
页码:69 / 73
页数:5
相关论文
共 35 条
[1]   SEROUS PAPILLARY CARCINOMA OF THE ENDOMETRIUM - A HISTOPATHOLOGICAL STUDY OF 22 CASES [J].
ABELER, VM ;
KJORSTAD, KE .
GYNECOLOGIC ONCOLOGY, 1990, 39 (03) :266-271
[2]  
[Anonymous], INT J GYNECOL OBSTET
[3]   UTERINE PAPILLARY SEROUS CARCINOMA - A STUDY ON 108 CASES WITH EMPHASIS ON THE PROGNOSTIC-SIGNIFICANCE OF ASSOCIATED ENDOMETRIOID CARCINOMA, ABSENCE OF INVASION, AND CONCOMITANT OVARIAN-CARCINOMA [J].
CARCANGIU, ML ;
CHAMBERS, JT .
GYNECOLOGIC ONCOLOGY, 1992, 47 (03) :298-305
[4]   Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide [J].
Chambers, JT ;
Chambers, SK ;
Kohorn, EI ;
Carcangiu, ML ;
Schwartz, PE .
GYNECOLOGIC ONCOLOGY, 1996, 60 (03) :438-442
[5]  
CHAMBERS JT, 1987, OBSTET GYNECOL, V69, P109
[6]   ENDOMETRIAL PAPILLARY ADENOCARCINOMAS - 2 CLINICOPATHOLOGICAL TYPES [J].
CHEN, JL ;
TROST, DC ;
WILKINSON, EJ .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1985, 4 (04) :279-288
[7]   THERAPEUTIC APPROACHES TO UTERINE PAPILLARY SEROUS CARCINOMA - A PRELIMINARY-REPORT [J].
CHRISTMAN, JE ;
KAPP, DS ;
HENDRICKSON, MR ;
HOWES, AE ;
BALLON, SC .
GYNECOLOGIC ONCOLOGY, 1987, 26 (02) :228-235
[8]  
CHRISTOPHERSON WM, 1982, AM J CLIN PATHOL, V77, P534
[9]   RISK-FACTORS AND RECURRENT PATTERNS IN STAGE-I ENDOMETRIAL CANCER [J].
DISAIA, PJ ;
CREASMAN, WT ;
BORONOW, RC ;
BLESSING, JA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1985, 151 (08) :1009-1015
[10]  
Dunton C J, 1991, Obstet Gynecol Surv, V46, P97, DOI 10.1097/00006254-199102000-00014